Usa Financial Portformulas Corp Supernus Pharmaceuticals, Inc. Transaction History

Usa Financial Portformulas Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Nov 27, 2023	SELL	$29.91 - $38.73 $5,533 - $7,165	-185 Reduced 5.11%	3,438 $103,000
Q1 2023 Nov 27, 2023	SELL	$34.93 - $42.03 $73,003 - $87,842	-2,090 Reduced 36.58%	3,623 $131,000
Q3 2022 Oct 24, 2022	BUY	$28.79 - $35.41 $164,477 - $202,297	5,713 New	5,713 $193,000
Q4 2017 Feb 13, 2018	SELL	$36.4 - $42.6 $280,571 - $328,360	-7,708 Closed	0 $0
Q3 2017 Oct 11, 2017	BUY	$36.75 - $49.65 $283,269 - $382,702	7,708	7,708 $308,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Usa Financial Portformulas Corp, based on Form 13F filings with the SEC.

Stay updated on Usa Financial Portformulas Corp with notifications on news.